Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Akero Therapeutics Inc

AKRO
Current price
19.5 USD +0.85 USD (+4.56%)
Last closed 18.32 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 1 266 846 336 USD
Yield for 12 month -55.57 %
1Y
3Y
5Y
10Y
15Y
AKRO
21.11.2021 - 28.11.2021

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California. Address: 601 Gateway Boulevard, South San Francisco, CA, United States, 94080

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

46.5 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

+284 000 USD

Current Year

-29 000 USD

Last Year

-260 000 USD

Current Quarter

-1 000 USD

Last Quarter

+282 000 USD

Key Figures AKRO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -204 052 000 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -20.23 %
PEG Ratio
Return On Equity TTM -31.11 %
Wall Street Target Price 46.5 USD
Revenue TTM
Book Value 12.24 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -3.24 USD
Diluted Eps TTM -3.24 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics AKRO

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History AKRO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation AKRO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -6.7701
Price Book MRQ 2.8581

Financials AKRO

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators AKRO

For 52 weeks

11.25 USD 58.38 USD
50 Day MA 21.94 USD
Shares Short Prior Month 8 601 700
200 Day MA 26.48 USD
Short Ratio 12.39
Shares Short 8 327 255
Short Percent 12.4 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

430.16 USD Microsoft Corporation +3.16 (+0.74%)
Detailed analytics

ETF funds


S

SX7EEX

14.70 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) +0.1 (+0.64%)
Detailed analytics

Metals


Gold

2357.98 USD Gold +6.23 (+0.27%)
Detailed analytics